DOJ Moves Medical Cannabis to Schedule III, Sets June 2026 Hearing
Justice Department finalizes medical cannabis rescheduling to Schedule III while announcing comprehensive cannabis reform hearings for summer 2026.
The Department of Justice has officially reclassified medical cannabis from Schedule I to Schedule III under the Controlled Substances Act, marking the most substantial federal cannabis policy shift in decades. The move removes medical cannabis from the same category as heroin and LSD, acknowledging its accepted medical use while maintaining federal oversight through the less restrictive Schedule III framework.
The rescheduling delivers immediate tax relief to state-licensed cannabis operators who have faced the punitive 280E tax provision that prohibited standard business deductions. Multi-state operators like Curaleaf Holdings, Green Thumb Industries, and Trulieve Cannabis Corp stand to benefit significantly from improved cash flows as they can now deduct operating expenses including rent, payroll, and marketing costs from federal taxes.
The Justice Department simultaneously announced comprehensive hearings scheduled for June 2026 to evaluate broader cannabis rescheduling beyond medical applications. This timeline suggests the Trump administration plans a methodical approach to federal cannabis reform rather than immediate descheduling, providing regulatory clarity that institutional investors have demanded before entering the cannabis sector.
The National Cannabis Industry Association praised the medical rescheduling while pushing for accelerated timelines on comprehensive reform. Industry stakeholders view the 2026 hearing date as conservative, given that adult-use cannabis operates legally in 24 states representing over 50% of the US population. The extended timeline may frustrate operators seeking full federal legalization but provides breathing room for companies to strengthen operations and balance sheets.
Cannabis equity markets should respond positively to the regulatory certainty, though the limited scope of current rescheduling may temper gains. The medical-only classification excludes the larger adult-use market from immediate federal benefits, maintaining the complex patchwork of state-federal cannabis laws that has constrained industry growth and institutional investment for over a decade.